What is the current valuation of the PARP Inhibitor Biomarkers Market?

The PARP Inhibitor Biomarkers Market was valued at 3.876 USD Billion in 2024. Read More

What is the projected market size for the PARP Inhibitor Biomarkers Market by 2035?

The market is expected to reach 15.84 USD Billion by 2035. Read More

What is the expected CAGR for the PARP Inhibitor Biomarkers Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 13.65%. Read More

What are the leading biomarker types in the PARP Inhibitor Biomarkers Market?

Key biomarker types include BRCA Mutations, PARP Expression, HRD Score, and Other Biomarkers. Read More

What applications are driving the PARP Inhibitor Biomarkers Market?

Applications such as Diagnosis, Prognosis, Treatment Selection, and Monitoring are driving market growth. Read More

Who are the key players in the PARP Inhibitor Biomarkers Market?

Key players include AstraZeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Roche, Novartis, Eli Lilly and Company, Clovis Oncology, and AbbVie. Read More

Which technologies are utilized in the PARP Inhibitor Biomarkers Market?

Technologies such as Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Fluorescence In Situ Hybridization (FISH) are utilized. Read More

How does the market performance vary across different cancer types?

In 2024, Breast Cancer accounted for 0.975 USD Billion, while Ovarian Cancer was valued at 0.825 USD Billion, indicating varied performance across cancer types. Read More

Parp Inhibitor Biomarkers Market

Q: Which cancer types are the primary focus in the PARP Inhibitor Biomarkers Market?

The primary cancer types include Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, and Other Cancers. Read More

Q: What are the primary end users of PARP inhibitors?

Primary end users include Hospitals, Diagnostic Laboratories, Pharmaceutical Companies, and Research Institutions. Read More

ID: MRFR/HC/25964-HCR

100 Pages

Rahul Gotadki

Last Updated: April 16, 2026

PARP Inhibitor Biomarkers Market Research Report By Cancer Type (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Other Cancers), By Biomarker Type (BRCA Mutations, PARP Expression, HRD Score, Other Biomarkers), By Application (Diagnosis, Prognosis, Treatment Selection, Monitoring, Other Applications), By End User (Hospitals, Diagnostic Laboratories, Pharmaceutical Companies, Research Institutions, Other End Users), By Technology (Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), Digital PCR, Other Technologies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Parp Inhibitor Biomarkers Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Cancer Type (USD Billion) | |
  1. 4.1.1 Breast Cancer | |
  2. 4.1.2 Ovarian Cancer | |
  3. 4.1.3 Prostate Cancer | |
  4. 4.1.4 Lung Cancer | |
  5. 4.1.5 Other Cancers |
2. 4.2 Healthcare, BY Biomarker Type (USD Billion) | |
  1. 4.2.1 BRCA Mutations | |
  2. 4.2.2 PARP Expression | |
  3. 4.2.3 HRD Score | |
  4. 4.2.4 Other Biomarkers |
3. 4.3 Healthcare, BY Application (USD Billion) | |
  1. 4.3.1 Diagnosis | |
  2. 4.3.2 Prognosis | |
  3. 4.3.3 Treatment Selection | |
  4. 4.3.4 Monitoring | |
  5. 4.3.5 Other Applications |
4. 4.4 Healthcare, BY End User (USD Billion) | |
  1. 4.4.1 Hospitals | |
  2. 4.4.2 Diagnostic Laboratories | |
  3. 4.4.3 Pharmaceutical Companies | |
  4. 4.4.4 Research Institutions | |
  5. 4.4.5 Other End Users |
5. 4.5 Healthcare, BY Technology (USD Billion) | |
  1. 4.5.1 Immunohistochemistry (IHC) | |
  2. 4.5.2 Next-Generation Sequencing (NGS) | |
  3. 4.5.3 Fluorescence In Situ Hybridization (FISH) | |
  4. 4.5.4 Digital PCR | |
  5. 4.5.5 Other Technologies |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 AstraZeneca (GB) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bristol-Myers Squibb (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Merck & Co. (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Pfizer (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Roche (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Novartis (CH) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Eli Lilly and Company (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Clovis Oncology (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 AbbVie (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY CANCER TYPE |
7. 6.4 US MARKET ANALYSIS BY BIOMARKER TYPE |
8. 6.5 US MARKET ANALYSIS BY APPLICATION |
9. 6.6 US MARKET ANALYSIS BY END USER |
10. 6.7 US MARKET ANALYSIS BY TECHNOLOGY |
11. 6.8 CANADA MARKET ANALYSIS BY CANCER TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY BIOMARKER TYPE |
13. 6.10 CANADA MARKET ANALYSIS BY APPLICATION |
14. 6.11 CANADA MARKET ANALYSIS BY END USER |
15. 6.12 CANADA MARKET ANALYSIS BY TECHNOLOGY |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY CANCER TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY BIOMARKER TYPE |
19. 6.16 GERMANY MARKET ANALYSIS BY APPLICATION |
20. 6.17 GERMANY MARKET ANALYSIS BY END USER |
21. 6.18 GERMANY MARKET ANALYSIS BY TECHNOLOGY |
22. 6.19 UK MARKET ANALYSIS BY CANCER TYPE |
23. 6.20 UK MARKET ANALYSIS BY BIOMARKER TYPE |
24. 6.21 UK MARKET ANALYSIS BY APPLICATION |
25. 6.22 UK MARKET ANALYSIS BY END USER |
26. 6.23 UK MARKET ANALYSIS BY TECHNOLOGY |
27. 6.24 FRANCE MARKET ANALYSIS BY CANCER TYPE |
28. 6.25 FRANCE MARKET ANALYSIS BY BIOMARKER TYPE |
29. 6.26 FRANCE MARKET ANALYSIS BY APPLICATION |
30. 6.27 FRANCE MARKET ANALYSIS BY END USER |
31. 6.28 FRANCE MARKET ANALYSIS BY TECHNOLOGY |
32. 6.29 RUSSIA MARKET ANALYSIS BY CANCER TYPE |
33. 6.30 RUSSIA MARKET ANALYSIS BY BIOMARKER TYPE |
34. 6.31 RUSSIA MARKET ANALYSIS BY APPLICATION |
35. 6.32 RUSSIA MARKET ANALYSIS BY END USER |
36. 6.33 RUSSIA MARKET ANALYSIS BY TECHNOLOGY |
37. 6.34 ITALY MARKET ANALYSIS BY CANCER TYPE |
38. 6.35 ITALY MARKET ANALYSIS BY BIOMARKER TYPE |
39. 6.36 ITALY MARKET ANALYSIS BY APPLICATION |
40. 6.37 ITALY MARKET ANALYSIS BY END USER |
41. 6.38 ITALY MARKET ANALYSIS BY TECHNOLOGY |
42. 6.39 SPAIN MARKET ANALYSIS BY CANCER TYPE |
43. 6.40 SPAIN MARKET ANALYSIS BY BIOMARKER TYPE |
44. 6.41 SPAIN MARKET ANALYSIS BY APPLICATION |
45. 6.42 SPAIN MARKET ANALYSIS BY END USER |
46. 6.43 SPAIN MARKET ANALYSIS BY TECHNOLOGY |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY BIOMARKER TYPE |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY END USER |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY CANCER TYPE |
54. 6.51 CHINA MARKET ANALYSIS BY BIOMARKER TYPE |
55. 6.52 CHINA MARKET ANALYSIS BY APPLICATION |
56. 6.53 CHINA MARKET ANALYSIS BY END USER |
57. 6.54 CHINA MARKET ANALYSIS BY TECHNOLOGY |
58. 6.55 INDIA MARKET ANALYSIS BY CANCER TYPE |
59. 6.56 INDIA MARKET ANALYSIS BY BIOMARKER TYPE |
60. 6.57 INDIA MARKET ANALYSIS BY APPLICATION |
61. 6.58 INDIA MARKET ANALYSIS BY END USER |
62. 6.59 INDIA MARKET ANALYSIS BY TECHNOLOGY |
63. 6.60 JAPAN MARKET ANALYSIS BY CANCER TYPE |
64. 6.61 JAPAN MARKET ANALYSIS BY BIOMARKER TYPE |
65. 6.62 JAPAN MARKET ANALYSIS BY APPLICATION |
66. 6.63 JAPAN MARKET ANALYSIS BY END USER |
67. 6.64 JAPAN MARKET ANALYSIS BY TECHNOLOGY |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY BIOMARKER TYPE |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY END USER |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY |
73. 6.70 MALAYSIA MARKET ANALYSIS BY CANCER TYPE |
74. 6.71 MALAYSIA MARKET ANALYSIS BY BIOMARKER TYPE |
75. 6.72 MALAYSIA MARKET ANALYSIS BY APPLICATION |
76. 6.73 MALAYSIA MARKET ANALYSIS BY END USER |
77. 6.74 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY |
78. 6.75 THAILAND MARKET ANALYSIS BY CANCER TYPE |
79. 6.76 THAILAND MARKET ANALYSIS BY BIOMARKER TYPE |
80. 6.77 THAILAND MARKET ANALYSIS BY APPLICATION |
81. 6.78 THAILAND MARKET ANALYSIS BY END USER |
82. 6.79 THAILAND MARKET ANALYSIS BY TECHNOLOGY |
83. 6.80 INDONESIA MARKET ANALYSIS BY CANCER TYPE |
84. 6.81 INDONESIA MARKET ANALYSIS BY BIOMARKER TYPE |
85. 6.82 INDONESIA MARKET ANALYSIS BY APPLICATION |
86. 6.83 INDONESIA MARKET ANALYSIS BY END USER |
87. 6.84 INDONESIA MARKET ANALYSIS BY TECHNOLOGY |
88. 6.85 REST OF APAC MARKET ANALYSIS BY CANCER TYPE |
89. 6.86 REST OF APAC MARKET ANALYSIS BY BIOMARKER TYPE |
90. 6.87 REST OF APAC MARKET ANALYSIS BY APPLICATION |
91. 6.88 REST OF APAC MARKET ANALYSIS BY END USER |
92. 6.89 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY CANCER TYPE |
95. 6.92 BRAZIL MARKET ANALYSIS BY BIOMARKER TYPE |
96. 6.93 BRAZIL MARKET ANALYSIS BY APPLICATION |
97. 6.94 BRAZIL MARKET ANALYSIS BY END USER |
98. 6.95 BRAZIL MARKET ANALYSIS BY TECHNOLOGY |
99. 6.96 MEXICO MARKET ANALYSIS BY CANCER TYPE |
100. 6.97 MEXICO MARKET ANALYSIS BY BIOMARKER TYPE |
101. 6.98 MEXICO MARKET ANALYSIS BY APPLICATION |
102. 6.99 MEXICO MARKET ANALYSIS BY END USER |
103. 6.100 MEXICO MARKET ANALYSIS BY TECHNOLOGY |
104. 6.101 ARGENTINA MARKET ANALYSIS BY CANCER TYPE |
105. 6.102 ARGENTINA MARKET ANALYSIS BY BIOMARKER TYPE |
106. 6.103 ARGENTINA MARKET ANALYSIS BY APPLICATION |
107. 6.104 ARGENTINA MARKET ANALYSIS BY END USER |
108. 6.105 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOMARKER TYPE |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY BIOMARKER TYPE |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY END USER |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY BIOMARKER TYPE |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY END USER |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY |
125. 6.122 REST OF MEA MARKET ANALYSIS BY CANCER TYPE |
126. 6.123 REST OF MEA MARKET ANALYSIS BY BIOMARKER TYPE |
127. 6.124 REST OF MEA MARKET ANALYSIS BY APPLICATION |
128. 6.125 REST OF MEA MARKET ANALYSIS BY END USER |
129. 6.126 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY BIOMARKER TYPE, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY BIOMARKER TYPE, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY END USER, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY APPLICATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY TECHNOLOGY, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Cancer Type (USD Billion, 2025-2035)

Breast Cancer
Ovarian Cancer
Prostate Cancer
Lung Cancer
Other Cancers

Healthcare By Biomarker Type (USD Billion, 2025-2035)

BRCA Mutations
PARP Expression
HRD Score
Other Biomarkers

Healthcare By Application (USD Billion, 2025-2035)

Diagnosis
Prognosis
Treatment Selection
Monitoring
Other Applications

Healthcare By End User (USD Billion, 2025-2035)

Hospitals
Diagnostic Laboratories
Pharmaceutical Companies
Research Institutions
Other End Users

Healthcare By Technology (USD Billion, 2025-2035)

Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Digital PCR
Other Technologies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓